Sionna Therapeutics Inc. (SION)
NASDAQ (NMS) NASDAQ (NMS) Primary 
Sionna Halts SION-719 After Phase 2a Miss, Eyes SION-451 Combination Path
Sionna Therapeutics NASDAQ: SION said its PreciSION CF Phase 2a proof-of-concept study of SION-719 added to Trikafta did not meet its key activity endpoint, prompting the company to discontinue development of SION-719 as an add-on to standard of care for cystic fibrosis.
Sionna Therapeutics, Inc. (SION) Discusses Clinical Trial Results and Discontinuation of 719 Program in Cystic Fibrosis Transcript
Sionna Therapeutics, Inc. (SION) Discusses Clinical Trial Results and Discontinuation of 719 Program in Cystic Fibrosis Transcript
Sionna Therapeutics: NBD1 Stabilization Could Redefine Cystic Fibrosis Treatment
Sionna Therapeutics targets cystic fibrosis with a novel NBD1 stabilization mechanism, aiming to enhance CFTR function beyond current standards. SION-719 as an add-on to Trikafta and SION-451 dual combinations both approach pivotal clinical readouts in summer 2026, offering dual strategic paths. Sionna's $289.9M cash runway extends to 2028, supporting critical proof-of-concept milestones without near-term financing risk.
This Investor Sold $5 Million of a Biotech Stock Up 118% in a Year, but Here's Why It Still Seems Bullish on Shares
OrbiMed Advisors sold 143,304 shares of Sionna Therapeutics in the fourth quarter; the estimated transaction value was $5.43 million based on quarterly average prices. Meanwhile, the quarter-end position value increased by $37.56 million, reflecting both trading and stock price movement.
A Sionna Therapeutics (SION) Insider Sold 33,000 Shares for $1.5 Million
33,356 shares sold for a transaction value of $1,486,009.80 on Dec. 24, 2025. Reducing total indirect ownership to 3,561,655 shares.
Sionna Therapeutics Seeks $100 Million in IPO For Cystic Fibrosis Treatments
Sionna Therapeutics aims to raise $100 million in an IPO to advance its cystic fibrosis drug candidates, currently in Phase 1 and Phase 2 trials. The firm is well-capitalized with $137.5 million in cash and backed by top-tier life science venture capital firms. The cystic fibrosis therapeutics market is projected to grow at a 14.2% CAGR, reaching $22.8 billion by 2030, offering significant market potential.
